Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
Company Growth (employees)
Chandler, US
Size (employees)
423 (est)-17%
Insys Therapeutics was founded in 1998 and is headquartered in Chandler, US

Key People/Management at Insys Therapeutics

Michael L. Babich

Michael L. Babich

Andrew Long

Andrew Long

Chief Financial Officer
Larry Dillaha

Larry Dillaha


Insys Therapeutics Office Locations

Insys Therapeutics has an office in Chandler
Chandler, US (HQ)
444 S Ellis Rd

Insys Therapeutics Financials and Metrics

Insys Therapeutics Financials

Insys Therapeutics's revenue was reported to be $36 m in Q1, 2017

Revenue (Q1, 2017)

36 m

Gross profit (Q1, 2017)

31.3 m

Gross profit margin (Q1, 2017), %


Net income (Q1, 2017)

(6.5 m)

EBIT (Q1, 2017)

(12.3 m)

Market capitalization (16-Oct-2017)

535.5 m

Cash (31-Mar-2017)

68.4 m
Insys Therapeutics's current market capitalization is $535.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


99.3 m222.1 m330.8 m242.3 m

Revenue growth, %


Cost of goods sold

12.7 m28.9 m25.4 m

Gross profit

86.6 m301.9 m216.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


55.7 m58.3 m70.8 m77.6 m91.3 m62 m67.1 m55.2 m36 m

Cost of goods sold

6.6 m5.4 m6.4 m8.3 m7.7 m4.6 m6.3 m4.7 m4.6 m

Gross profit

49.1 m52.9 m64.4 m69.3 m83.6 m57.3 m60.8 m50.5 m31.3 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


45.4 m58.1 m79.5 m104.6 m


14.5 m34.8 m41.7 m21.7 m

Current Assets

82.2 m151 m253.2 m231 m


10.1 m38.4 m43.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


46.1 m47.4 m70.1 m74 m94 m73.8 m69.3 m93.5 m68.4 m


24.7 m31.4 m35.2 m35.6 m39.4 m32.2 m29.2 m28 m21.3 m

Current Assets

102.2 m128.7 m182.1 m198.2 m236.6 m220.8 m234 m235.2 m196.9 m


17.4 m24.1 m33.8 m35.5 m36.7 m39.6 m39.9 m41.3 m46 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

40.4 m58.5 m7.6 m

Depreciation and Amortization

1.8 m2.5 m5.3 m6.2 m

Accounts Receivable

(13 m)(10 m)(22 m)26.6 m


(7.4 m)(20 m)(6.9 m)15 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

9.5 m11.5 m8 m7.3 m26.1 m2.4 m4.4 m190 k(6.5 m)


24.7 m31.4 m35.2 m35.6 m39.4 m32.2 m29.2 m28 m

Accounts Payable

15.1 m24.5 m36.6 m30.6 m24.2 m25.7 m22.2 m17.5 m28.2 m
USDY, 2017


77.1 k

Financial Leverage

1.3 x
Show all financial metrics

Insys Therapeutics Market Value History

Insys Therapeutics Median Salaries

Source: 24 public H-1B filings from Insys Therapeutics

Traffic Overview of Insys Therapeutics

Insys Therapeutics Company Life and Culture

You may also be interested in